Our lead program candidate, STAR-0215, is a potential best-in-class monoclonal antibody inhibitor of plasma kallikrein that is in clinical development for the treatment of hereditary angioedema. We initiated a Phase 1a clinical trial in 2022, and anticipate preliminary results by year-end.
Learn how STAR-0215 aims to prevent attacks in HAE by exploring the mechanism of action here:
Pending positive results from the Phase 1a trial, we expect to initiate a multi-center, global Phase 1b/2 trial in people living with HAE in 2023.
We are working to reduce the treatment burden for people living with HAE, whose current options for preventative therapies require frequent administration. We believe we can do better with STAR-0215.
Our goal is to provide the most patient-friendly preventative treatment option, with dosing once every 3 months or longer, for people living with HAE.